These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Canakinumab for secondary prevention of coronary artery disease. Ortega-Paz L; Capodanno D; Angiolillo DJ Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
5. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610 [TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ; Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629 [TBL] [Abstract][Full Text] [Related]
8. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ; Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493 [TBL] [Abstract][Full Text] [Related]
13. Canakinumab in gout. Schlesinger N Expert Opin Biol Ther; 2012 Sep; 12(9):1265-75. PubMed ID: 22784099 [TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870 [TBL] [Abstract][Full Text] [Related]
15. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
16. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of Inflammation in Cardiovascular Disease. Martinez BK; White CM Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210 [TBL] [Abstract][Full Text] [Related]
18. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Ridker PM J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883 [TBL] [Abstract][Full Text] [Related]
19. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
20. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]